TMO Stock Up 8.9% after 7-Day Win Streak
Thermo Fisher Scientific (TMO) stock hit day 7 of a continuous streak of days with gains, with cumulative gains over this period amounting to a 8.9% return. The company has gained about $16 Bil in value over the last 7 days, with its current market capitalization at about $183 Bil. The stock remains 5.8% below its value at the end of 2024. This compares with year-to-date returns of 9.7% for the S&P 500.
TMO provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products worldwide for research, drug production, diagnostics, and laboratory equipment needs. After this rally, is TMO still a buy – or is it time to lock in gains? Deep dive with Buy or Sell TMO.
Comparing TMO Stock Returns With The S&P 500
The following table summarizes the return for TMO stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | TMO | S&P 500 |
|---|---|---|
| 1D | 0.8% | -0.3% |
| 7D (Current Streak) | 8.9% | 1.7% |
| 1M (21D) | 15.1% | 2.4% |
| 3M (63D) | 20.9% | 9.0% |
| YTD 2025 | -5.8% | 9.7% |
| 2024 | -1.7% | 23.3% |
| 2023 | -3.4% | 24.2% |
| 2022 | -17.3% | -19.4% |
What is the point? Momentum often precedes conviction. A multi-day win streak can signal growing investor confidence or spark follow-on buying. Tracking such trends can help you ride the strength, or prepare for a well-timed entry if momentum fades.
Gains and Losses Streaks: S&P 500 Constituents
There are currently 35 S&P constituents with 3 days or more of consecutive gains and 27 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 9 | 24 |
| 4D | 16 | 2 |
| 5D | 4 | 0 |
| 6D | 1 | 1 |
| 7D or more | 5 | 0 |
| Total >=3 D | 35 | 27 |
Key Financials for Thermo Fisher Scientific (TMO)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | $42.9 Bil | $42.9 Bil |
| Operating Income | $7.3 Bil | $7.7 Bil |
| Net Income | $6.0 Bil | $6.3 Bil |
Last 2 Fiscal Quarters:
| Metric | 2024 FQ4 | 2025 FQ1 |
|---|---|---|
| Revenues | $11.4 Bil | $10.4 Bil |
| Operating Income | $2.2 Bil | $1.8 Bil |
| Net Income | $1.8 Bil | $1.5 Bil |
While TMO stock looks attractive given its winning streak, investing in a single stock without detailed, thorough analysis can be risky. The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 – the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.